secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2024-02-21T23:59:59+00:00
Accession:  0001082554-24-000007
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics reports record $2.33B 2023 revenue (+20% YoY); sues FDA over Liquidia NDA amendment
--------------------------------------------------------------------------------

- FY 2023 revenue $2.33B, net income $984.8M ($19.81 diluted EPS).
- Tyvaso revenue grew 41% to $1.23B; Tyvaso DPI rose 362% to $731M.
- Q4 2023 revenue $614.7M (+25% YoY), net income $217.1M (diluted EPS $4.36).
- Filed lawsuit against FDA alleging agency improperly allowed Liquidia to amend pending NDA for PH-ILD, avoiding a 30-month stay of approval.
- Litigation seeks to enforce Hatch-Waxman patent infringement stay pending resolution of separate patent case against Liquidia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255424000007/0001082554-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255424000007/uthr-20240221.htm
  HTML page:      https://secwatch.observer/filing/0001082554-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer